We are live on ! Find out more
FPC

Falcon Point Capital Portfolio holdings

AUM $11.9M
1-Year Est. Return 55.76%
This Fund
S&P 500
This Quarter Est. Return
+16.28%
1 Year Est. Return
+55.76%
3 Year Est. Return
+118.89%
5 Year Est. Return
+197.9%
10 Year Est. Return
AUM
$184M
AUM Growth
+$16.3M
Cap. Flow
-$7.35M
Cap. Flow %
-4.01%
Top 10 Hldgs %
29.96%
Holding
117
New
14
Increased
35
Reduced
41
Closed
11

Sector Composition

Rank Sector Weight
1 Industrials 22.8%
2 Technology 18.55%
3 Healthcare 15.74%
4 Consumer Discretionary 11.45%
5 Financials 6.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TPC
101
Tutor Perini Cor
TPC
$4.03B
-23,522
Closed -$376K
TWNK
102
DELISTED
Hostess Brands, Inc. Class A Common Stock
TWNK
-227,126
Closed -$2.48M
ATRS
103
DELISTED
Antares Pharma, Inc.
ATRS
-130,200
Closed -$354K
CARB
104
DELISTED
Carbonite Inc
CARB
-17,660
Closed -$446K
ESIO
105
DELISTED
Electro Scientific Industries
ESIO
-11,238
Closed -$337K
GG
106
DELISTED
Goldcorp Inc
GG
-11,855
Closed -$116K

Similar funds

Falcon Point Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Falcon Point Capital held 117 positions worth $184M, up 9.7% from $167M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Falcon Point Capital withdrew a net $7.35M in Q1 2019, closing 11 positions and reducing 41 holdings. Its most notable exit was Supernus Pharmaceuticals, an estimated $2.7M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 23% of assets, up from 20% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Falcon Point Capital opened a new position in Merit Medical Systems worth $3.78M.

  • Falcon Point Capital's largest Q1 2019 buy was Merit Medical Systems: 61,087 shares worth $3.78M.
  • Falcon Point Capital added most to Cardiovascular Systems, Inc. in Q1 2019, an estimated $4.23M increase.
  • Falcon Point Capital's biggest Q1 2019 reduction was Omnicell, cutting an estimated $3.17M.
  • Falcon Point Capital fully exited Supernus Pharmaceuticals in Q1 2019, selling an estimated $2.7M.
  • Falcon Point Capital's ten largest holdings make up 30% of its $184M portfolio in Q1 2019.
  • Falcon Point Capital opened 14 new positions and closed 11 in Q1 2019.
  • Falcon Point Capital's portfolio value rose 9.7% quarter-over-quarter to $184M.

Based on Falcon Point Capital's 13F filing for Q1 2019, filed 8 May 2019.